



US009174975B2

(12) **United States Patent**  
**Nakamura et al.**

(10) **Patent No.:** **US 9,174,975 B2**  
(45) **Date of Patent:** **\*Nov. 3, 2015**

(54) **REMEDY FOR INTEGRATION  
DYSFUNCTION SYNDROME**

(75) Inventors: **Mitsutaka Nakamura**, Osaka (JP);  
**Masaaki Ogasa**, Osaka (JP); **Shunsuke  
Sami**, Osaka (JP)

(73) Assignee: **SUMITOMO DAINIPPON PHARMA  
CO., LTD**, Osaka (JP)

(\* ) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 1040 days.  
  
This patent is subject to a terminal dis-  
claimer.

(21) Appl. No.: **10/525,021**

(22) PCT Filed: **Aug. 20, 2003**

(86) PCT No.: **PCT/JP03/10490**  
§ 371 (c)(1),  
(2), (4) Date: **Feb. 18, 2005**

(87) PCT Pub. No.: **WO2004/017973**  
PCT Pub. Date: **Mar. 4, 2004**

(65) **Prior Publication Data**  
US 2006/0025422 A1 Feb. 2, 2006

**Related U.S. Application Data**

(60) Provisional application No. 60/404,927, filed on Aug.  
22, 2002.

(51) **Int. Cl.**  
**A61K 9/00** (2006.01)  
**C07D 417/12** (2006.01)  
**A61K 31/496** (2006.01)

(52) **U.S. Cl.**  
CPC ..... **C07D 417/12** (2013.01); **A61K 31/496**  
(2013.01)

(58) **Field of Classification Search**  
USPC ..... 514/254.04  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

5,444,073 A 8/1995 Perregaard et al.  
5,532,372 A 7/1996 Saji et al.  
5,780,632 A 7/1998 Saji et al.  
6,964,962 B2\* 11/2005 Wong et al. .... 514/239.2  
7,067,507 B2 6/2006 Pulley et al.  
2003/0050307 A1 3/2003 Ruhland et al.  
2006/0025422 A1 2/2006 Nakamura et al.  
2006/0111429 A1 5/2006 Fish et al.  
2006/0142276 A1 6/2006 Ohno et al.  
2008/0255148 A1 10/2008 Ohno et al.

**FOREIGN PATENT DOCUMENTS**

EP 4 648 46 A1 1/1992  
JP 0464846 \* 5/1991  
JP 05-17440 A 1/1993  
JP 6-504787 A 6/1994  
JP 08-333368 12/1996  
JP 2000-281576 10/2000  
JP 2003-135074 A 5/2003  
JP 2003-160583 6/2003  
JP 2003-519226 A 6/2003  
WO 93/16073 8/1993  
WO WO 95/34306 12/1995  
WO WO 96/14297 5/1996  
WO WO 99/52519 10/1999  
WO WO 02/22581 A1 3/2002  
WO WO-02/24166 A1 3/2002  
WO WO03066039 A1 \* 8/2003 ..... A61K 31/19  
WO WO 2004/017973 3/2004  
WO WO 2004/113333 12/2004  
WO WO 2007/124757 A2 11/2007  
WO WO 2008/124030 10/2008

**OTHER PUBLICATIONS**

Current Opinion in Neurobiology 2000, 10:205-210, Schizophrenia  
and cognitive function.\*  
New York, NY, US: Guilford Press. (1994). xii 212 pp.\*  
Kay, Stanley R. et al., The Positive and Negative Syndrome Scale  
(PANSS) for Schizophrenia, Schizophrenia Bulletin, vol. 13, No. 2,  
1987, pp. 261-276.  
"Delirium, Dementia, Amnesia, Cognitive Disorders," [http://www.nlm.nih.gov/cgi/mesh/2009/MB\\_cgi?mode=&term=.m,+Dementia,+Amnestic,+Cognitive+Disorders&field=entry](http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?mode=&term=.m,+Dementia,+Amnestic,+Cognitive+Disorders&field=entry),  
accessed Jul. 1, 2009.  
Alphs, Larry, "An industry perspective on the NIMH Consensus  
Statement on negative symptoms," Schizophrenia Bulletin, vol. 32,  
No. 2, pp. 225-230, (2006).  
Approval Labeling Text, NDA 21-487, for NAMENDA™  
(memantine hydrochloride) (2003).  
Barber, Teresa A., et al., "Memantine ameliorates scopolamine-in-  
duced amnesia in chicks trained on taste-avoidance learning,"  
Neurobiology of Learning and Memory, vol. 93, pp. 540-545, (2010).  
Bejar, Corina, et al., "Effect of rivastigmine on scopolamine-induced  
memory impairment in rats," European Journal of Pharmacology,  
vol. 383, pp. 231-240, (1999).  
Biederman, Joseph, et al., "Risperidone treatments for ADHD in  
children and adolescents with bipolar disorder," Neuropsychiatric  
Diseases and Treatment, vol. 4, No. 1, pp. 203-207 (2008).

(Continued)

*Primary Examiner* — Snigdha Maewall

(74) *Attorney, Agent, or Firm* — Finnegan Henderson  
Farabow Garrett & Dunner LLP

(57) **ABSTRACT**

The present invention provides a novel method for treatment  
of schizophrenia which can improve wide-ranging symptoms  
of schizophrenia, especially positive symptoms and negative  
symptoms without being accompanied by extrapyramidal  
symptoms, which comprises orally administering as an active  
compound (1R,2S,3R,4S)—N-[(1R,2R)-2-[4-(1,2-ben-  
zoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylm-  
ethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide or a phar-  
maceutically acceptable salt thereof (e.g., hydrochloride) at a  
daily dose of 5 mg to 120 mg once a day to a patient with  
schizophrenia, and a therapeutic agent to be used in the  
method.

(56)

## References Cited

## OTHER PUBLICATIONS

- Botero, Hector M. et al., "Structure—Activity Relationships in a Series of Bisquaternary Bisphthalimidine Derivatives Modulating the Muscarinic M2-Receptor Allosterically," *J. Med. Chem.*, vol. 43, pp. 2155-2164, (2000).
- Bowen, D.M., "Traditional pharmacotherapy may succeed in alzheimer's disease," *Trends in Neurosciences*, vol. 15, No. 3, pp. 84-85, (1992).
- Bruno, et al., "The  $\alpha 2c$ -adrenergic receptor mediates hyperactivity of colobomo mice, a model of attention deficit hyperactivity disorder," *Neurobiology of Disease*, vol. 23, pp. 679-688, (2006).
- Center for Drug Evaluation and Research, *Pharmacology Reviews at FDA*, pp. 1-260, (Oct. 2010).
- Clinton et al., "Altered transcript expression of NMDA, receptor associated postsynaptic proteins in the thalamus of subject with schizophrenia," *Am. J. Psychiatry*, vol. 160, No. 6, pp. 1100-1109, (Jun. 2003).
- Clinton et al., "Thalamic expression of NMDA receptor-associated postsynaptic density proteins in schizophrenia," *Society for Neuroscience, Program No. 754.4*, (2003), (online) (abstract only).
- Cloninger, "The discovery of susceptibility genes for mental disorders," *Proc. Natl. Acad. Sci.*, vol. 99, No. 21, pp. 13365-13367, (Oct. 15, 2002).
- Corbett, "Clozapine but not haloperidol antagonizes an MK-801 discriminative stimulus cue," *Pharmacol. Biochem. Behav.*, vol. 51(2-3), pp. 561-564, (1995).
- Didriksen, et al., "Antipsychotic potential of the Gly T-1 inhibitor NFPS," *Society Neuroscience Abstract*, vol. 2002, abstract No. 893. 1, (2002).
- Doggrell, Sheila A. et al., "Treatment of dementia with neurotransmission modulation," *Expert Opinion on Investigational Drugs*, vol. 12, No. 10, pp. 1633-1654, (2003).
- Duka, Theodora, "Scopolamine-induced amnesia in humans: Lack of effects of the benzodiazepine receptor antagonist  $\beta$ -carboline ZK 93426," *Journal of Psychopharmacology*, vol. 6, No. 3, pp. 382-388, Abstract, (1992).
- Ebihara, Mitsuru et al., "Togo Scicchosho no Dobutsu Model," *Igaku no Ayumi*, vol. 208, No. 3, pp. 138-142, (2004).
- Emre, Murat, M.D. et al., "Rivastigmine for dementia associated with parkinson's disease," *The New England Journal of Medicine*, vol. 351, No. 24, pp. 2509-2518, (2004).
- English translation of Office Action from the Chinese Patent Office in Appln. No. 200480017534.X dated Jan. 29, 2010.
- English translation of Office Action from the Japanese Patent Office in Appln. No. 2005-507314 dated Jun. 29, 2010.
- English translation of Second Office Action from the Chinese Patent Office in Appln. No. 200480017534.X dated Jan. 29, 2010.
- Enomoto et al., "Development of antipsychotics by using animal model," *Brain Science*, vol. 25, No. 5, pp. 437-444 (2003).
- EP Official Action for Corresponding EP Application No. 04 746 564.6-2117 dated Aug. 27, 2010.
- EP Official Action for Corresponding EP Application No. 04 746 564.6-2117 dated Nov. 20, 2009.
- EP Search Report for European Patent Application No. 04746564.6 dated Mar. 2, 2009.
- EP Search Report for European Patent Application No. 11160001.1-2123 dated Jul. 19, 2011.
- Erhart, Stephen M., et al., "Treatment of schizophrenia negative symptoms: future prospects," *Schizophrenia Bulletin*, vol. 32, No. 2, pp. 234-237, 2006.
- European Neuropsychopharmacology, "P.3.155 Efficacy of lurasidone (SM-13496) in the treatment of schizophrenia: results of two, phase 2, placebo-controlled studies," vol. 15, pp. S522-S523, (2005).
- Fabre, Serge et al., "Protein Kinase C Inhibitors: Structure—Activity Relationships in K252c-Related Compounds," *Bioorg. Med. Chem.*, vol. 1, No. 3, pp. 193-196, (1993).
- Fernandez, Hubert H. et al., "Pharmacotherapy of dementia with Final Office Action in U.S. Appl. No. 12/140,927 dated Jul. 10, 2009. Final Office Action in U.S. Appl. No. 12/140,927 dated Jul. 18, 2011.
- Friedman, Joseph I., "Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists," *Psychopharmacology*, 174, pp. 45-53, (2004).
- Geyer et al., "Animal behavior models of the mechanisms underlying antipsychotic atypicality," *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, vol. 27, pp. 1071-1079, (2003).
- Goff et al., "The emerging role of glutamate in the pathophysiology and treatment of schizophrenia," *Am. J. Psychiatry*, vol. 158, No. 9, pp. 1367-1377, (Sep. 2001).
- Harrod et al., "MK-801 induced retrieval, but not acquisition, deficits for passive avoidance conditioning," *Pharmacology, Biochemistry, and Behavior*, vol. 69, pp. 585-593, (2001).
- Harvey et al., "Cognition in schizophrenia: from basic science to clinical treatment," *Psychopharmacology*, vol. 169, pp. 213-214, (2003).
- Harvey et al., "Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness," *J. Clin. Psychiatry*, vol. 65, pp. 361-372, (2004).
- Hyman et al., "What are the right targets for psychopharmacology?" *Science*, vol. 299, pp. 350-351, (Jan. 17, 2003).
- Ibrahim et al., "Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia," *Am. J. Psychiatry*, vol. 159, No. 11, pp. 1811-1823, (Nov. 2000).
- International Search Report for International Application No. PCT/JP2004/009095 dated Aug. 24, 2004.
- International Search Report for International Application No. PCT/JP2011/062314 dated Jun. 28, 2011.
- Ishiyama, T., et al., "Effects on sm-13496, a novel serotonin-dopamine antagonist, and other antipsychotics on cognitive performance in rat passive avoidance test," abstract, vol. 23, (2003).
- Ishizumi, Kikuo, et al., "Succinimide Derivatives. II. Synthesis and Antipsychotic Activity of N-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis-cyclohexanedicarboximide (SM-9018) and Related Compounds," *Chem. Pharm. Bull.*, vol. 43, No. 12, pp. 2139-2151, (1995).
- Japanese Office Action in corresponding Japanese Application No. 2006-510283 dated May 31, 2011.
- Jellinger, Kurt A., "The Pathology of Ischemic-Vascular Dementia: An Update," *Journal of the Neurological Sciences* 203-204, pp. 153-157, (2002).
- Kahle, Philipp J. et al., "The Emerging Utility of Animal Models of Chronic Neurodegenerative Diseases," *Emerging Therapeutic Targets*, vol. 5, No. 1, 125-132, (2001).
- Kane, John, "Commentary: Consensus statement on negative symptoms," *Schizophrenia Bulletin*, vol. 32, No. 2, pp. 223-224, (2006).
- Kasper et al., "Cognitive effects and antipsychotic treatment," *Psychoneuroendocrinology*, vol. 28, pp. 27-38, (2003).
- Kirkpatrick, Brian, et al., "The NIMH-MATRICES consensus statement on negative symptoms," vol. 32, No. 2, pp. 214-219, (2006).
- Krystal et al., "NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development," *Psychopharmacology*, vol. 169, pp. 215-233, (2003).
- Laughren, Thomas, et al., "Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim," *Schizophrenia Bulletin*, vol. 32, No. 2, pp. 220-222, (2006).
- Malenka et al., "Long term potentiation—A decade of progress?" *Science*, vol. 285, pp. 1870-1874, (Sep. 17, 1999).
- Masi, Gabriele, et al., "Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders," *CNS Drugs*, vol. 23, No. 6, pp. 511-521, (2009).
- Meltzer et al., "Cognition, schizophrenia, and the atypical antipsychotic drugs," *Proc. Natl. Acad. Sci.*, vol. 96, No. 24, pp. 13591-13593, (Nov. 23, 1999).
- Mettey Y, et al., "Synthesis of 11-Aminodibenzol[b,f][1,4]thiazepines and Fluoro Derivatives,"

(56)

## References Cited

## OTHER PUBLICATIONS

- Meyer, Jonathan, M. et al., "Lurasidone: a new drug in development for schizophrenia," *Expert Opinion on Investigational Drugs*, vol. 18, No. 11, pp. 1715-1726, (2006).
- Misane et al., "Selective 5-HT<sub>1A</sub> Antagonists WAY 10065 and NAD-299 Attenuate the Impairment of Passive Avoidance Caused by Scopolamine in the Rat," *Neuropsychopharmacology* 28, pp. 253-264, (2003).
- Miyachi, Hiroyuki et al., "Novel Biological Response Modifiers: Phthalimides with Tumor Necrosis Factor- $\alpha$  Production-Regulating Activity," *J. Med. Chem.*, vol. 40, pp. 2858-2865, (1997).
- Miyamoto et al., "Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor E1 subunit," *Journal of Neuroscience*, vol. 21, No. 2, pp. 750-757, (Jan. 15, 2001).
- Moghaddam, "Bringing order to the glutamate chaos in schizophrenia," *Neuron*, vol. 40, pp. 881-884, (Dec. 4, 2003).
- Mohn et al., "Mice with reduced NMDA receptor expression display behaviors related to schizophrenia," *Cell*, vol. 98, pp. 427-436, (1999).
- Myhrer, "Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks," *Brain Research Reviews*, vol. 41, pp. 268-287, (2003).
- Nakagawa et al., "Ethanol-induced state-dependent learning is mediated by 5-hydroxytryptamine<sub>3</sub> receptors but not by N-methyl-D-aspartate receptor complex," *Brain Research*, vol. 706, pp. 227-232, (1996).
- Nippon-Shinkei-Seishin-Yakurigaku Zasshi (Jpn. J. Neuropsychopharmacol.) 23: 296 (2003).
- Noda et al., "Clozapine, but not haloperidol, reverses working memory impairment induced by chronic PCP administration in rats: a new model for cognitive dysfunction in schizophrenia," *Abstracts Society Neuroscience*, vol. 26, Nos. 1-2, pp. 6533, (2000).
- Norman, Mark H. et al., "Effect of Linking Bridge Modifications on the Antipsychotic Profile of Some Phthalimide and Isoindolinone Derivatives," *Journal of Medical Chemistry*, vol. 39, No. 1, pp. 149-157, (1996).
- Notice of Allowance and Fees Due in U.S. Appl. No. 12/140,927, dated Dec. 1, 2011.
- Office Action in Japanese Application No. 2005-507314 issued on Jun. 29, 2010 (4 pages).
- Office Action in U.S. Appl. No. 12/140,927 dated Nov. 10, 2010.
- Office Action in U.S. Appl. No. 13/113,703, mailed Nov. 22, 2011.
- Ogasa et al., "SM-13496 in patients with acute exacerbation of schizophrenia: A two-dose double-blind phase II comparison with placebo," *Schizophrenia Research*, vol. 60, No. 1, pp. 297, (2003).
- Parnetti, et al., "Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation?," *Journal of the Neurological Sciences*, vol. 257, pp. 264-269, (2007).
- Perry, Elaine et al., "Acetylcholine in Mind: a Neurotransmitter Correlate of Consciousness?," *TINS*, vol. 22, No. 6, pp. 273-280 (1999). Poster exhibited at the 18th European College of Neuropsychopharmacology Congress, Oct. 23-26, 2005.
- Powell, Susan, B., et al., "RO-10-5824 is a selective dopamine D4 receptor agonist that increases novel object exploration in C57 mice," *Neuropharmacology*, vol. 44, pp. 473-481, (2003).
- Prescribing information for "Exelon® (rivastigmine tartrate) Capsules and Oral Solution," (31 pages), (2006).
- Prescribing Information for ARICEPT® (donepezil hydrochloride) (14 pages) (2010).
- Protais, P. et al., "Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum," *Psychopharmacology*, vol. 50, pp. 1-6, (1976).
- Puttress, et al., "Localized deletion of the NR1 gene in mouse prefrontal cortex impairs spatial memory," *Society Neuroscience Abstract*, vol. 2003, abstract No. 964.19, (2003).
- Reingold, Jennifer L. et al., "Rivastigmine for the Treatment of Roman, Gustavo C. et al., "Donepezil in Vascular Dementia: Combined Analysis of Two Large-Scale Clinical Trials," *Dementia and Geriatr. Cogn. Disord.*, vol. 20 pp. 337-344, (2005).
- Romero, Arthur G. et al., "Synthesis of Metabolically Stable Arylpiperazine 5-HT<sub>1A</sub> Receptor Agonists," *Bioorganic & Medicinal Chemistry Letters*, vol. 2, No. 12, pp. 1703-1706, (1992).
- Russell, Vivienne, A., et al., "Animal models of attention-deficit hyperactivity disorder," *Behavioral and Brain Functions*, vol. 1, No. 9, pp. 1-17, (2005).
- Rutten, K., et al., "Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques," *Psychopharmacology*, vol. 196, pp. 643-648, (2008).
- Sharma et al., "Cognitive function in schizophrenia deficits, functional consequences, and future treatment," *Psychiatr. Clin. N. Am.*, vol. 26, pp. 25-40, (2003).
- Shinkei Kairomo Keisei to Kofunsei Synapse Kasosei ni Kansura Kodogakuteki Kenkyu. pp. 13-2, with partial English language translation. (2003).
- Small, David H., "Acetylcholinesterase Inhibitors for the Treatment of Dementia in Alzheimer's Disease: Do We Need New Inhibitors?," *Expert Opinion on Emerging Drugs*, vol. 10, No. 4, pp. 817-823, (2005).
- Snyder, Peter J. et al., "Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor," *Alzheimer's & Dementia*, vol. 1, pp. 126-135, (2005).
- Takahashi, Satoshi et al., "Anti-Dementia Drugs and Vascular Dementia," *Rinsho-Seishinigaku, (Clinical Psychiatry)*, vol. 31, No. 10, pp. 1189-1193, (2002).
- The Lancet, "The Treatment of Senile Insanity," *Lancet Limited*, London, GB LNKD-DOI:10.1016/S0140-6736 (01) 05083-8, vol. 208, No. 5381, pp. 820-882, (Oct. 16, 1926).
- Thomas, Elizabeth et al., "Specific Impairments in Visuospatial Working and Short-Term Memory Following Low-Dose Scopolamine Challenge in Healthy Older Adults," *Neuropsychologia*, vol. 46, pp. 2476-2484, (2008).
- Tokita, Kenichi et al., "Combination of a Novel Antidementia Drug FK960 with Donepezil Synergistically Improves Memory Deficits in Rats," *Pharmacology, Biochemistry and Behavior*, vol. 73, pp. 511-519, (2002).
- Tokuda, et al., "Effects of SM-13496, an atypical antipsychotic agent, on MK-801-induced learning deficit in rats," *J. Pharmacol Sciences*, vol. 94, supplement 1, p. 163P, (2004).
- Turetsky et al., "Memory-Delineated Subtypes of Schizophrenia: Relationship to Clinical, Neuroanatomical, and Neurophysiological Measures," *Neuropsychology*, vol. 16, No. 4, pp. 481-490 (2002).
- Wang, D., et al., "Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model," *Neuropharmacology*, vol. 52, pp. 1179-1187 (2007).
- Weiss et al., "The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia," *Psychopharmacology*, vol. 162, pp. 11-17, (2002).
- Wise, L.E., et al., "Reversal learning in the 8-arm radial maze in rats is impaired by subchronic administration of the non-competitive NMDA antagonist ketamine," *Society for Neuroscience*, abstract, vol. 2002, (2002).
- Woolley et al., "Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat," *Behavioural Pharmacology*, vol. 19, Iss. 8, pp. 765-776, (Dec. 2008).
- Xu Taixiang et al., "Status quo and Development of Alzheimer's Disease," *Acta Academiae Medicinae Qingdao Universitatis*, vol. 37, No. 4, pp. 355-357, (2001).
- Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV™) pp. 273-278, 285, and 286 (1994), published by the American Psychiatric Association, Washington D.C.
- Kay et al., *Schizophrenia Bulletin*, vol. 13, No. 2, pp. 261-276 (1987).
- Lindenmayer et al., *Psychiatric Quarterly*, vol. 65, No. 4, pp. 299-322 (1994).
- Perricone v. Medicis Pharm. Corp.*, 432 F.3d 1368 (Fed. Cir. 2005).

(56)


**References Cited**

OTHER PUBLICATIONS

Office Action in U.S. Appl. No. 12/140,927 (continuation of U.S. Appl. No. 10/562,039) mailed Oct. 3, 2008.  
Office Action in U.S. Appl. No. 12/140,927 mailed Oct. 19, 2009.

U.S. Appl. No. 10/589,804, filed Aug. 17, 2006.  
Office Action in U.S. Appl. No. 10/589,804 mailed Dec. 11, 2008.  
Office Action in U.S. Appl. No. 12/401,958 (continuation of U.S. Appl. No. 10/589,804) mailed Oct. 1, 2009.  
Office Action in U.S. Appl. No. 12/401,958 mailed Apr. 5, 2010.

\* cited by examiner



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.